Loading…
Loading…
ProShares Ultra Health Care (NYSEARCA:RXL - Get Free Report) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totaling 931 shares, a decline of 13.7% from the March 15th total of 1,079 shares. Based on an average trading volume of 9,353 shares, the short-interest
ProShares Ultra Health Care (NYSEARCA:RXL - Get Free Report)'s stock price crossed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $49.61 and traded as low as $46.08. ProShares Ultra Health Care shares last traded at $46.16, with a volume of 7,180 shares. ProShares Ultra Health
ProShares Ultra Health Care (NYSEARCA:RXL - Get Free Report)'s stock price crossed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $48.97 and traded as high as $52.22. ProShares Ultra Health Care shares last traded at $51.75, with a volume of 3,556 shares. ProShares
With a new year comes the opportunity to make changes, and that's what ProShares has done by swapping benchmarks on 23 ETFs, largely focused on their inverse and leveraged strategies.
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of this year, as operations that were disrupted return to normal.
The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets.
The issuers were among a number of firms making changes to expense ratios and enacting splits.